Wei Zhang

Wei Zhang

Auto-generated profile, based on publicly available information

Wei Zhang

Laboratory of Cellular and Molecular Biology, Center for Cancer Research National Cancer Institute, National Institutes of Health Bethesda MD USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SJSarah Jenkins
Sarah Jenkins
WZWei Zhang
Wei Zhang
SSSeth M. Steinberg
Seth M. Steinberg
DNDarryl Nousome
Darryl Nousome
NHNicole Houston
Nicole Houston
AZAlexandra S. Zimmer
Alexandra S. Zimmer
Purpose: Preclinical data showed that prophylactic, low-dose temozolomide (TMZ) significantly prevented breast cancer brain metastasis. We present results of a phase I trial combining T-DM1 with TMZ for the prevention of additional brain metastases after previous occurrence and local treatment in patients with HER2+ breast cancer. Patients and Methods: Eligible patients had HER2+ breast cancer with brain metastases and were within 12 weeks of whole brain radiation therapy (WBRT), stereotactic radiosurgery, and/or surgery. Standard doses of T-DM1 were administered intravenously every 21 days (3.6 mg/kg) and TMZ was given orally daily in a 3+3 phase I dose escalation design at 30, 40, or 50 mg/m2, continuously. DLT period was one 21-day cycle. Primary endpoint was safety and recommended phase II dose. Symptom questionnaires, brain MRI, and systemic CT scans were performed every 6 weeks. Cell-free DNA sequencing was performed on patients’ plasma and CSF. Results: Twelve women enrolled, nine (75%) with prior SRS therapy and three (25%) with prior WBRT. Grade 3 or 4 AEs included thrombocytopenia (1/12), neutropenia (1/12), lymphopenia (6/12), and decreased CD4 (6/12), requiring pentamidine for Pneumocystis jirovecii pneumonia prophylaxis. No DLT was observed. Four patients on the highest TMZ dose underwent dose reductions. At trial entry, 6 of 12 patients had tumor mutations in CSF, indicating ongoing metastatic colonization despite a clear MRI. Median follow-up on study was 9.6 m (2.8–33.9); only 2 patients developed new parenchymal brain metastases. Tumor mutations varied with patient outcome. Conclusions: Metronomic TMZ in combination with standard dose T-DM1 shows low-grade toxicity and potential activity in secondary prevention of HER2+ brain metastases.

25 November 2025
Verified
Other
Open access
SJSarah Jenkins
Sarah Jenkins
WZWei Zhang
Wei Zhang
SSSeth M. Steinberg
Seth M. Steinberg
DNDarryl Nousome
Darryl Nousome
NHNicole Houston
Nicole Houston
AZAlexandra S. Zimmer
Alexandra S. Zimmer
Supplemental Fig. 4. Histogram illustrating ERBB2 relative copy number in plasma and CSF cfDNA samples from 12 patients during their T samples from 12 patients during their Tsamples from 12 patients during their T samples from 12 patients during their T-DM1/TMZ combination therapy.

14 April 2023
Verified
Other
Open access
SJSarah Jenkins
Sarah Jenkins
WZWei Zhang
Wei Zhang
SSSeth M. Steinberg
Seth M. Steinberg
DNDarryl Nousome
Darryl Nousome
NHNicole Houston
Nicole Houston
AZAlexandra S. Zimmer
Alexandra S. Zimmer
Supplemental Fig. 3. ERB-B-2 Status of Patients.



14 April 2023
Verified
Other
Open access
SJSarah Jenkins
Sarah Jenkins
WZWei Zhang
Wei Zhang
SSSeth M. Steinberg
Seth M. Steinberg
DNDarryl Nousome
Darryl Nousome
NHNicole Houston
Nicole Houston
AZAlexandra S. Zimmer
Alexandra S. Zimmer
Supplemental Fig 2. Total mutation Burden by MB.